MiMedx Board Member Boosts Stake with Annual Stock Grant - Shows Long-term Commitment

Rhea-AI Filing Summary

MiMedx Group director Cato T. Laurencin acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing their total direct holdings to 181,923 shares.

The transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. Key details about the grant:

• Vesting occurs at the earlier of 12 months or next annual shareholder meeting
• Transaction was filed as a Form 4 pursuant to Section 16(a) of Securities Exchange Act
• The acquisition was reported as a direct ownership transaction

This insider transaction indicates ongoing compensation practices for board members and alignment with shareholder interests through equity-based compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAURENCIN CATO T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	28,609	$6.47	$185K

Holdings After Transaction: Common Stock — 181,923 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAURENCIN CATO T

(Last) (First) (Middle)

1775 WEST OAK COMMONS COURT NE

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		28,609(1)	A	$6.47	181,923	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders

Remarks:

	/s/ William F. Hulse as attorney-in-fact for Cato T. Laurencin	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director Cato T. Laurencin acquire on June 18, 2025?

Director Cato T. Laurencin acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the total number of MDXG shares owned by Cato Laurencin after the June 2025 transaction?

Following the reported transaction, Cato T. Laurencin directly owned 181,923 shares of MDXG common stock.

What are the vesting terms for MDXG's director stock grant in 2025?

The restricted stock grant vests upon the earlier of either 12 months from the grant date or the next annual meeting of shareholders. The grant is exempt under Rule 16b-3 of the Securities Exchange Act.

Where is MDXG Director Cato Laurencin based according to the Form 4?

According to the Form 4 filing, Director Cato T. Laurencin's address is listed as 1775 West Oak Commons Court NE, Marietta, GA 30062.